PRCT
PROCEPT BioRobotics Corporation NASDAQ Listed Sep 15, 2021$25.48
Mkt Cap $1.5B
52w Low $19.35
12.9% of range
52w High $66.85
50d MA $25.03
200d MA $32.81
P/E (TTM)
-14.3x
EV/EBITDA
-19.0x
P/B
3.8x
Debt/Equity
0.1x
ROE
-26.1%
P/FCF
-30.1x
RSI (14)
—
ATR (14)
—
Beta
0.93
50d MA
$25.03
200d MA
$32.81
Avg Volume
1.7M
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
900 Island Drive · San Jose, CA 94065 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | AMC | -0.55 | -0.56 | -1.8% | 21.71 | +10.9% | +10.7% | +13.4% | +14.4% | +16.0% | +14.2% | — |
| Feb 25, 2026 | AMC | -0.32 | -0.53 | -65.6% | 27.84 | -29.6% | -15.1% | -18.5% | -7.0% | -5.7% | -4.6% | — |
| Nov 4, 2025 | AMC | -0.41 | -0.38 | +7.3% | 35.02 | -6.5% | -9.7% | -10.6% | -8.9% | -11.7% | -10.5% | — |
| Aug 6, 2025 | AMC | -0.41 | -0.35 | +14.6% | 45.69 | -8.1% | -13.4% | -15.9% | -15.1% | -15.5% | -11.6% | — |
| Apr 24, 2025 | AMC | -0.49 | -0.45 | +8.2% | 52.56 | -1.1% | -0.1% | +3.0% | +7.1% | +2.7% | +0.6% | — |
| Feb 25, 2025 | AMC | -0.34 | -0.35 | -2.9% | 62.71 | +4.5% | +8.6% | +3.7% | +2.6% | -3.4% | +3.6% | — |
| Oct 28, 2024 | AMC | -0.48 | -0.40 | +16.7% | 91.00 | -3.3% | +6.3% | +2.2% | -1.1% | +1.4% | +6.7% | — |
| Aug 1, 2024 | AMC | -0.52 | -0.50 | +3.8% | 62.00 | -4.9% | -7.5% | -9.2% | -2.3% | -3.1% | -0.2% | — |
| May 1, 2024 | AMC | -0.55 | -0.51 | +7.3% | 60.61 | +3.3% | +1.9% | +6.1% | +1.4% | +3.6% | -0.4% | — |
| Feb 27, 2024 | AMC | -0.44 | -0.54 | -22.7% | 50.75 | -5.4% | -2.7% | -4.7% | -3.3% | -5.7% | -8.6% | — |
| Nov 1, 2023 | AMC | -0.53 | -0.51 | +3.8% | 27.55 | +8.0% | +18.4% | +23.1% | +19.1% | +20.1% | +19.3% | — |
| Jul 27, 2023 | AMC | -0.57 | -0.56 | +1.8% | 35.13 | +1.6% | +0.4% | -2.0% | -3.5% | +2.5% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.71 | $24.08 | +10.9% | +10.7% | +13.4% | +14.4% | +16.0% | +14.2% |
| Mar 2 | Truist | Maintains | Buy → Buy | — | $22.69 | $22.16 | -2.3% | +14.1% | +15.7% | +17.1% | +11.7% | +6.7% |
| Feb 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $27.84 | $19.61 | -29.6% | -15.1% | -18.5% | -7.0% | -5.7% | -4.6% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $27.84 | $19.61 | -29.6% | -15.1% | -18.5% | -7.0% | -5.7% | -4.6% |
| Feb 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.84 | $19.61 | -29.6% | -15.1% | -18.5% | -7.0% | -5.7% | -4.6% |
| Feb 26 | Oppenheimer | Downgrade | Outperform → Perform | — | $27.84 | $19.61 | -29.6% | -15.1% | -18.5% | -7.0% | -5.7% | -4.6% |
| Feb 26 | Leerink Partners | Maintains | Outperform → Outperform | — | $27.84 | $19.61 | -29.6% | -15.1% | -18.5% | -7.0% | -5.7% | -4.6% |
| Feb 26 | BofA Securities | Downgrade | Neutral → Underperform | — | $27.84 | $19.61 | -29.6% | -15.1% | -18.5% | -7.0% | -5.7% | -4.6% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $33.78 | $34.30 | +1.5% | -3.1% | -5.1% | +1.4% | -3.1% | -2.7% |
| Dec 8 | BofA Securities | Downgrade | Buy → Neutral | — | $35.86 | $33.62 | -6.2% | -5.1% | -2.4% | -0.4% | +0.5% | +0.4% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.41 | $30.38 | -0.1% | -2.9% | +9.1% | +16.5% | +17.9% | +11.9% |
| Nov 5 | TD Cowen | Maintains | Buy → Buy | — | $35.02 | $32.73 | -6.5% | -9.7% | -10.6% | -8.9% | -11.7% | -10.5% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $35.02 | $32.73 | -6.5% | -9.7% | -10.6% | -8.9% | -11.7% | -10.5% |
| Nov 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $35.02 | $32.73 | -6.5% | -9.7% | -10.6% | -8.9% | -11.7% | -10.5% |
| Oct 15 | Truist | Maintains | Buy → Buy | — | $33.92 | $33.85 | -0.2% | -0.5% | +0.1% | -2.8% | +2.4% | +2.0% |
| Sep 16 | BTIG | Maintains | Neutral → Neutral | — | $38.00 | $37.89 | -0.3% | +4.1% | -1.9% | +0.1% | -1.6% | +1.2% |
| Sep 2 | Oppenheimer | Upgrade | Perform → Outperform | — | $40.17 | $41.89 | +4.3% | -1.5% | -5.8% | -4.6% | +1.3% | -3.1% |
| Aug 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $45.69 | $42.00 | -8.1% | -13.4% | -15.9% | -15.1% | -15.5% | -11.6% |
| Aug 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $45.69 | $42.00 | -8.1% | -13.4% | -15.9% | -15.1% | -15.5% | -11.6% |
| Jul 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $58.17 | $58.35 | +0.3% | -0.3% | -1.9% | +1.3% | +0.3% | -1.9% |
| Apr 25 | BofA Securities | Maintains | Buy → Buy | — | $52.56 | $51.96 | -1.1% | -0.1% | +3.0% | +7.1% | +2.7% | +0.6% |
| Apr 11 | Truist | Maintains | Buy → Buy | — | $50.73 | $50.60 | -0.3% | +2.6% | +6.0% | +4.3% | +4.1% | +4.5% |
| Feb 26 | Truist | Maintains | Buy → Buy | — | $62.71 | $65.56 | +4.5% | +8.6% | +3.7% | +2.6% | -3.4% | +3.6% |
| Feb 26 | Morgan Stanley | Maintains | Overweight → Overweight | — | $62.71 | $65.56 | +4.5% | +8.6% | +3.7% | +2.6% | -3.4% | +3.6% |
| Oct 30 | Truist | Maintains | Buy → Buy | — | $96.69 | $97.00 | +0.3% | -3.8% | -6.9% | -4.6% | +0.4% | -1.3% |
| Oct 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $69.62 | $73.50 | +5.6% | +6.3% | +6.5% | +3.9% | +3.0% | +4.8% |
| Sep 16 | TD Cowen | Maintains | Buy → Buy | — | $81.11 | $82.86 | +2.2% | +1.1% | -1.6% | +2.3% | +2.1% | +4.8% |
| Sep 3 | Truist | Maintains | Buy → Buy | — | $79.00 | $78.14 | -1.1% | -5.0% | -3.8% | -3.4% | -3.0% | -2.9% |
| Aug 22 | BofA Securities | Maintains | Buy → Buy | — | $83.44 | $85.50 | +2.5% | -3.8% | -4.9% | -6.5% | -2.4% | -4.1% |
| Aug 2 | Wells Fargo | Maintains | Overweight → Overweight | — | $62.00 | $58.95 | -4.9% | -7.5% | -9.2% | -2.3% | -3.1% | -0.2% |
| Aug 2 | Truist | Maintains | Buy → Buy | — | $62.00 | $58.95 | -4.9% | -7.5% | -9.2% | -2.3% | -3.1% | -0.2% |
| Jul 16 | Truist | Maintains | Buy → Buy | — | $66.84 | $67.85 | +1.5% | +4.4% | +6.6% | -0.1% | +0.9% | +3.4% |
| May 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $64.31 | $65.00 | +1.1% | -4.5% | -2.4% | -6.1% | -2.0% | -2.6% |
| May 6 | TD Cowen | Maintains | Buy → Buy | — | $64.31 | $65.00 | +1.1% | -4.5% | -2.4% | -6.1% | -2.0% | -2.6% |
| May 2 | Truist | Maintains | Buy → Buy | — | $60.61 | $62.63 | +3.3% | +1.9% | +6.1% | +1.4% | +3.6% | -0.4% |
| Feb 28 | Truist | Maintains | Buy → Buy | — | $50.75 | $48.00 | -5.4% | -2.7% | -4.7% | -3.3% | -5.7% | -8.6% |
| Jan 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $42.21 | $42.98 | +1.8% | +15.1% | +12.7% | +11.5% | +10.9% | +11.7% |
| Dec 22 | Truist | Maintains | Buy → Buy | — | $42.55 | $43.07 | +1.2% | -1.1% | +0.3% | +1.0% | +0.9% | -1.5% |
| Dec 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $39.36 | $39.79 | +1.1% | +3.0% | +6.7% | +10.3% | +7.4% | +6.8% |
| Sep 13 | Truist | Maintains | Buy → Buy | — | $33.98 | $33.97 | -0.0% | -0.7% | -2.4% | -3.4% | -2.7% | -2.4% |
| May 31 | William Blair | Maintains | Outperform → Outperform | — | $31.40 | $31.82 | +1.3% | +6.5% | +3.5% | +3.5% | +0.4% | +6.8% |
| May 1 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $30.39 | $29.49 | -3.0% | +3.0% | -6.1% | -4.2% | -5.2% | -6.1% |
| May 1 | Truist | Maintains | Buy → Buy | — | $30.39 | $29.49 | -3.0% | +3.0% | -6.1% | -4.2% | -5.2% | -6.1% |
| Apr 28 | Truist | Maintains | Buy → Buy | — | $26.70 | $26.78 | +0.3% | +13.8% | +17.2% | +6.9% | +9.1% | +7.9% |
| Apr 28 | BofA Securities | Maintains | Buy → Buy | — | $26.70 | $26.78 | +0.3% | +13.8% | +17.2% | +6.9% | +9.1% | +7.9% |
| Jan 31 | Truist | Maintains | Buy → Buy | — | $37.55 | $37.75 | +0.5% | +3.6% | +4.2% | +5.6% | +4.1% | -1.9% |
| Jan 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $32.49 | $32.38 | -0.3% | +4.3% | +12.3% | +20.4% | +21.2% | +18.7% |
| Dec 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $42.81 | $43.06 | +0.6% | +0.5% | +3.9% | -1.5% | -1.3% | +0.4% |
| Nov 4 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $44.00 | $39.24 | -10.8% | -9.4% | -10.8% | -8.0% | -10.5% | +1.2% |
| Nov 4 | Goldman Sachs | Maintains | Neutral → Neutral | — | $44.00 | $39.24 | -10.8% | -9.4% | -10.8% | -8.0% | -10.5% | +1.2% |
No insider trades available.
8-K
PROCEPT BioRobotics Corporation -- 8-K Filing
PROCEPT BioRobotics reported Q1 2026 results, emphasizing operational restructuring toward accountability and commercial discipline in its surgical robotics urology focus.
Apr 29
8-K
PROCEPT BioRobotics Corporation -- 8-K Filing
Puckett's appointment to a senior finance or operations role at PROCEPT BioRobotics brings extensive experience from Forest Laboratories and Affymetrix, potentially strengthening the company's operational and financial management capabilities.
Mar 6
8-K · 7.01
! Medium
PROCEPT BioRobotics Corporation -- 8-K 7.01: Regulation FD Disclosure
PROCEPT BioRobotics disclosed its Investor Day presentation, providing investors access to updated company guidance and strategic messaging through live and archived recordings on its investor relations website.
Feb 26
8-K
PROCEPT BioRobotics Corporation -- 8-K Filing
PROCEPT BioRobotics reported record Q4 2025 procedure volume of 12,200 and sold 65 new robotic systems, demonstrating strong surgical adoption momentum in its urology-focused business.
Feb 25
Data updated apr 26, 2026 8:35pm
· Source: massive.com